Pub. Date : 2009 Jan 15
PMID : 19147568
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Here, we report that DFMO treatment, but not Odc heterozygosity, impairs MYCN-induced neuroblastoma and that, in this malignancy, transient DFMO treatment is sufficient to confer protection. | Eflornithine | MYCN proto-oncogene, bHLH transcription factor | Homo sapiens |
| 2 | The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins. | Eflornithine | MYCN proto-oncogene, bHLH transcription factor | Homo sapiens |
| 3 | The selective anticancer effects of DFMO on mouse and human MYCN-amplified neuroblastoma also rely on its ability to disable the proliferative response of Myc, yet in this tumor context, DFMO targets the expression of the p21(Cip1) Cdk inhibitor, which is also suppressed by Myc oncoproteins. | Eflornithine | MYCN proto-oncogene, bHLH transcription factor | Homo sapiens |
| 4 | These findings suggest that agents, such as DFMO, that target the polyamine pathway may show efficacy in high-risk, MYCN-amplified neuroblastoma. | Eflornithine | MYCN proto-oncogene, bHLH transcription factor | Homo sapiens |